Monopar Therapeutics (MNPR) Cash from Financing Activities (2017 - 2025)
Monopar Therapeutics (MNPR) reported Cash from Financing Activities of -$384680.0 for Q4 2025, down 100.69% on a YoY basis from $56.1 million in Q4 2024, and down 100.42% sequentially from $92.4 million in Q3 2025.
Monopar Therapeutics (MNPR) Cash from Financing Activities (2017 - 2025) Analysis & Trends
Monopar Therapeutics (MNPR) has 9 years of Cash from Financing Activities data on file, last reported at -$384680.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities fell 100.69% year-over-year to -$384680.0; the trailing twelve-month figure through Dec 2025 stood at $91.6 million (up 54.45% YoY), and the FY2025 full-year result was $91.6 million, up 54.45% from the prior year.
- Cash from Financing Activities retreated to -$384680.0 in Q4 2025, from $92.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $92.4 million in Q3 2025 to a low of -$384680.0 in Q4 2025.
- A 5-year average of $8.2 million and a median of -$8845.5 in 2021 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 558897.68% in 2025, while the deepest fall reached 3094.32% in 2025.
- Tracing MNPR's Cash from Financing Activities over 5 years: stood at -$7772.0 in 2021, then soared by 1885.09% to $138737.0 in 2022, then jumped by 141.14% to $334548.0 in 2023, then jumped by 16679.9% to $56.1 million in 2024, then tumbled by 100.69% to -$384680.0 in 2025.
- Business Quant data shows MNPR's Cash from Financing Activities at -$384680.0 in Q4 2025, $92.4 million in Q3 2025, and -$316845.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Monopar Therapeutics | 707.36 Mn | 645.53 Mn | - | -384,680.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -384,680.00 |
| Dec 31, 2025 | -384,680.00 |
| Sep 30, 2025 | 92.39 Mn |
| Sep 30, 2025 | 92.39 Mn |
| Jun 30, 2025 | -316,845.00 |
| Jun 30, 2025 | -316,845.00 |
| Mar 31, 2025 | -115,682.00 |
| Mar 31, 2025 | -115,682.00 |
| Dec 31, 2024 | 56.14 Mn |
| Dec 31, 2024 | 56.14 Mn |
| Sep 30, 2024 | -16,534.00 |
| Sep 30, 2024 | -16,534.00 |
| Jun 30, 2024 | -9,919.00 |
| Jun 30, 2024 | -9,919.00 |
| Mar 31, 2024 | 3.18 Mn |
| Mar 31, 2024 | 3.18 Mn |
| Dec 31, 2023 | 334,548.00 |
| Dec 31, 2023 | 334,548.00 |
| Sep 30, 2023 | 246,703.00 |
| Sep 30, 2023 | 246,703.00 |